North America Dry Eye Disease Market Forecast 2024-2032

The North America dry eye disease market is expected to grow at a CAGR of 5.12% during the forecast period of 2024 to 2032. The market was valued at $2283.72 million in 2032, reaching a projected revenue of $3604.57 million by 2032.

MARKET INSIGHTS

The rising geriatric population in North America is a significant factor contributing to the growing number of cases of dry eye diseases. Older individuals are more prone to conditions affecting tear production, leading to common dry eye disease symptoms such as dryness, burning, and blurred vision. Environmental factors and lifestyle changes, including increased screen time, are also contributing to the increasing prevalence of dry eye disease across all age groups.

REGIONAL ANALYSIS

The North America dry eye disease market growth analysis includes a detailed examination of the United States and Canada. Technological advancements in therapeutic and diagnostic products are facilitating more effective treatment for dry eye disease. New dry eye disease treatment drugs and products, including artificial tears and anti-inflammatory medications, are improving patient outcomes. Moreover, the demand for dry eye disease treatment devices is on the rise, as these devices help enhance tear production and alleviate symptoms. Innovations in eye drops and treatment technologies are addressing the need for more efficient and targeted solutions.

In the United States, a National Health and Wellness Survey reports that 6.8% of the adult population is affected by dry eye disease, with prevalence increasing with age and being higher in females compared to males. Further analysis from the 2017 National Health and Wellness Survey (NHWS) indicates that the gender disparity in dry eye disease prevalence widens as age increases. Consequently, healthcare professionals expect a rise in cases of dry eye syndrome among the aging population.

Additionally, product launches and innovations by major companies are poised to boost market opportunities. For example, in 2022, Bausch + Lomb presented data from a second pivotal Phase 3 trial for their investigational treatment, NOV03. This would be the first pharmaceutical therapy in the United States featuring a new mechanism of action specifically targeting the relief of dry eye symptoms related to Meibomian gland dysfunction.

SEGMENTATION ANALYSIS

The North America dry eye disease market segmentation includes type, product, dosage, and distribution channel. The type segment is further classified into OTC and prescription.

Over-the-counter (OTC) treatments, including artificial tears and lubricating eye drops, are widely used products by patients for quick relief from dry eye disease symptoms. Leading players in this segment include Johnson & Johnson, which provides a variety of eye care products aimed at addressing dry eye symptoms. Companies such as Alcon and Allergan PLC also play a significant role in the OTC segment with their range of treatments for dry eye disease.

While the demand for anti-inflammatory drugs and treatment devices continues to rise, one of the challenges facing the market is the underdiagnosis of dry eye disease. Many patients remain unaware of their condition or do not seek proper treatment. However, increasing awareness through educational initiatives and improved access to diagnostic tools are expected to boost diagnosis rates, allowing for more effective management of the disease.

COMPETITIVE INSIGHTS

Some of the key firms operating in the North America dry eye disease market are Novartis AG, Novaliq GmbH, Lumenis, Oasis Medical, etc.

Oasis Medical Inc, headquartered in Los Angeles, California, is a specialized manufacturer of surgical supplies, instruments, disposables, and eye care products. The company produces a wide range of products aimed at treating retinal diseases, dry eye disease, refractive errors, and cataracts. One of its flagship products, Oasis TEARS(R) PF PLUS Preservative-Free Lubricant Eye Drops, is designed to combat dry eye, offering viscoadaptive properties and strong adherence for effective relief.

Product Code: 95049

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON THE DRY EYE DISEASE MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. PROLONGED SCREEN EXPOSURE CAN TRIGGER SYMPTOMS OF DRY EYE
- 2.5.2. INDIVIDUALS OF ASIAN DESCENT ARE MORE SUSCEPTIBLE TO DEVELOPING DRY EYE DISEASE
- 2.5.3. AIR POLLUTION IS A SIGNIFICANT CONTRIBUTOR TO EYE-RELATED CONDITIONS
- 2.5.4. THE COVID-19 PANDEMIC HAS LED TO A SURGE IN DRY EYE DISEASE CASES

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. RISING INCIDENCE AND PREVALENCE OF DRY EYE AMONG VARIOUS AGE GROUPS
- 3.1.2. LAUNCH OF PIPELINE PRODUCTS FOR THE TREATMENT OF DRY EYE DISEASE
- 3.1.3. INTRODUCTION OF NEW DIAGNOSTIC TECHNIQUES FOR DRY EYE DISEASE
3.2. KEY RESTRAINTS
- 3.2.1. RISK OF SIDE EFFECTS ASSOCIATED WITH TREATMENTS
- 3.2.2. AVAILABILITY OF ALTERNATIVE THERAPIES
- 3.2.3. HIGH COSTS OF SPECIALTY PRODUCTS AND A COMPLEX REIMBURSEMENT LANDSCAPE

4. KEY ANALYTICS

4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
- 4.2.1. EMERGING STEM CELL THERAPY IN THE TREATMENT OF DRY EYE DISEASE
4.3. PORTER'S FIVE FORCES ANALYSIS
- 4.3.1. BUYERS POWER
- 4.3.2. SUPPLIERS POWER
- 4.3.3. SUBSTITUTION
- 4.3.4. NEW ENTRANTS
- 4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
- 4.4.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA DRY EYE DISEASE MARKET
4.5. MARKET MATURITY ANALYSIS
4.6. MARKET CONCENTRATION ANALYSIS
4.7. VALUE CHAIN ANALYSIS
- 4.7.1. RESEARCH AND DEVELOPMENT
- 4.7.2. MANUFACTURING
- 4.7.3. DISTRIBUTORS
- 4.7.4. POST-SALES MONITORING

5. MARKET BY TYPE

5.1. OTC
5.2. PRESCRIPTION

6. MARKET BY PRODUCT

6.1. ANTI-INFLAMMATORY DRUGS
- 6.1.1. CYCLOSPORINE
- 6.1.2. CORTICOSTEROID
- 6.1.3. OTHER ANTI-INFLAMMATORY DRUGS
6.2. ARTIFICIAL TEARS
6.3. PUNCTAL PLUGS
6.4. SECRETAGOGUES
6.5. OTHER PRODUCTS

7. MARKET BY DOSAGE

7.1. EYE DROPS
7.2. EYE SOLUTIONS
7.3. OINTMENTS
7.4. GELS
7.5. CAPSULES & TABLETS

8. MARKET BY DISTRIBUTION CHANNEL

8.1. HOSPITAL PHARMACIES
8.2. INDEPENDENT PHARMACIES AND DRUG STORES
8.3. ONLINE PHARMACIES/STORES

9. GEOGRAPHICAL ANALYSIS

9.1. NORTH AMERICA
- 9.1.1. MARKET SIZE & ESTIMATES
- 9.1.2. NORTH AMERICA DRY EYE DISEASE MARKET DRIVERS
- 9.1.3. NORTH AMERICA DRY EYE DISEASE MARKET CHALLENGES
- 9.1.4. NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
- 9.1.5. KEY PLAYERS IN NORTH AMERICA DRY EYE DISEASE MARKET
- 9.1.6. COUNTRY ANALYSIS
  - 9.1.6.1. UNITED STATES
  - 9.1.6.1.1. UNITED STATES DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES
  - 9.1.6.2. CANADA
  - 9.1.6.2.1. CANADA DRY EYE DISEASE MARKET SIZE & OPPORTUNITIES

10. COMPETITIVE LANDSCAPE

10.1. KEY STRATEGIC DEVELOPMENTS
- 10.1.1. MERGERS & ACQUISITIONS
- 10.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 10.1.3. PARTNERSHIPS & AGREEMENTS
- 10.1.4. BUSINESS EXPANSIONS & DIVESTITURES
10.2. COMPANY PROFILES
- 10.2.1. ALCON
  - 10.2.1.1. COMPANY OVERVIEW
  - 10.2.1.2. PRODUCT LIST
  - 10.2.1.3. STRENGTHS & CHALLENGES
- 10.2.2. ALLERGAN PLC (ACQUIRED BY ABBVIE)
  - 10.2.2.1. COMPANY OVERVIEW
  - 10.2.2.2. PRODUCT LIST
  - 10.2.2.3. STRENGTHS & CHALLENGES
- 10.2.3. BAUSCH HEALTH COMPANIES INC
  - 10.2.3.1. COMPANY OVERVIEW
  - 10.2.3.2. PRODUCT LIST
  - 10.2.3.3. STRENGTHS & CHALLENGES
- 10.2.4. JOHNSON & JOHNSON
  - 10.2.4.1. COMPANY OVERVIEW
  - 10.2.4.2. PRODUCT LIST
  - 10.2.4.3. STRENGTHS & CHALLENGES
- 10.2.5. AFT PHARMACEUTICALS
  - 10.2.5.1. COMPANY OVERVIEW
  - 10.2.5.2. PRODUCT LIST
  - 10.2.5.3. STRENGTHS & CHALLENGES
- 10.2.6. LUMENIS
  - 10.2.6.1. COMPANY OVERVIEW
  - 10.2.6.2. PRODUCT LIST
  - 10.2.6.3. STRENGTHS & CHALLENGES
- 10.2.7. NOVALIQ GMBH
  - 10.2.7.1. COMPANY OVERVIEW
  - 10.2.7.2. PRODUCT LIST
  - 10.2.7.3. STRENGTHS & CHALLENGES
- 10.2.8. OASIS MEDICAL
  - 10.2.8.1. COMPANY OVERVIEW
  - 10.2.8.2. PRODUCTS LIST
  - 10.2.8.3. STRENGTHS & CHALLENGES
- 10.2.9. OTSUKA PHARMACEUTICAL CO LTD
  - 10.2.9.1. COMPANY OVERVIEW
  - 10.2.9.2. PRODUCT LIST
  - 10.2.9.3. STRENGTHS & CHALLENGES
- 10.2.10. SANTEN PHARMACEUTICAL CO LTD
  - 10.2.10.1. COMPANY OVERVIEW
  - 10.2.10.2. PRODUCTS LIST
  - 10.2.10.3. STRENGTHS & CHALLENGES
- 10.2.11. NOVARTIS AG
  - 10.2.11.1. COMPANY OVERVIEW
  - 10.2.11.2. PRODUCT LIST
  - 10.2.11.3. STRENGTHS & CHALLENGES
- 10.2.12. SENTISS PHARMA PRIVATE LIMITED
  - 10.2.12.1. COMPANY OVERVIEW
  - 10.2.12.2. PRODUCTS LIST
  - 10.2.12.3. STRENGTHS & CHALLENGES
- 10.2.13. TEVA PHARMACEUTICAL INDUSTRIES LTD
  - 10.2.13.1. COMPANY OVERVIEW
  - 10.2.13.2. PRODUCT LIST
  - 10.2.13.3. STRENGTHS & CHALLENGES
- 10.2.14. SUN PHARMACEUTICAL INDUSTRIES LTD
  - 10.2.14.1. COMPANY OVERVIEW
  - 10.2.14.2. PRODUCT LIST
  - 10.2.14.3. STRENGTHS & CHALLENGES
- 10.2.15. VISUFARMA
  - 10.2.15.1. COMPANY OVERVIEW
  - 10.2.15.2. PRODUCT LIST
  - 10.2.15.3. STRENGTHS & CHALLENGES

Product Code: 95049

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT - DRY EYE DISEASE MARKET
TABLE 2: NORTH AMERICA DRY EYE DISEASE MARKET REGULATORY FRAMEWORK
TABLE 3: NORTH AMERICA DRY EYE DISEASE MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 4: NORTH AMERICA DRY EYE DISEASE MARKET, BY TYPE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 5: NORTH AMERICA DRY EYE DISEASE MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 6: NORTH AMERICA DRY EYE DISEASE MARKET, BY PRODUCT, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 7: NORTH AMERICA DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 8: NORTH AMERICA DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 9: NORTH AMERICA DRY EYE DISEASE MARKET, BY DOSAGE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 10: NORTH AMERICA DRY EYE DISEASE MARKET, BY DOSAGE, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 11: NORTH AMERICA DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 12: NORTH AMERICA DRY EYE DISEASE MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 13: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 14: NORTH AMERICA DRY EYE DISEASE MARKET, BY COUNTRY, FORECAST YEARS, 2024-2032 (IN $ MILLION)
TABLE 15: KEY PLAYERS OPERATING IN NORTH AMERICA DRY EYE DISEASE MARKET
TABLE 16: LIST OF MERGERS & ACQUISITIONS
TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS
TABLE 19: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS
FIGURE 2: PORTER'S FIVE FORCES ANALYSIS
FIGURE 3: GROWTH PROSPECT MAPPING FOR NORTH AMERICA DRY EYE DISEASE MARKET
FIGURE 4: MARKET MATURITY ANALYSIS
FIGURE 5: MARKET CONCENTRATION ANALYSIS
FIGURE 6: VALUE CHAIN ANALYSIS
FIGURE 7: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY TYPE, IN 2023
FIGURE 8: NORTH AMERICA DRY EYE DISEASE MARKET, BY OTC, 2024-2032 (IN $ MILLION)
FIGURE 9: NORTH AMERICA DRY EYE DISEASE MARKET, BY PRESCRIPTION, 2024-2032 (IN $ MILLION)
FIGURE 10: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2023
FIGURE 11: NORTH AMERICA DRY EYE DISEASE MARKET, BY ANTI-INFLAMMATORY DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 12: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY ANTI-INFLAMMATORY DRUGS, IN 2023
FIGURE 13: NORTH AMERICA DRY EYE DISEASE MARKET, BY CYCLOSPORINE, 2024-2032 (IN $ MILLION)
FIGURE 14: NORTH AMERICA DRY EYE DISEASE MARKET, BY CORTICOSTEROID, 2024-2032 (IN $ MILLION)
FIGURE 15: NORTH AMERICA DRY EYE DISEASE MARKET, BY OTHER ANTI-INFLAMMATORY DRUGS, 2024-2032 (IN $ MILLION)
FIGURE 16: NORTH AMERICA DRY EYE DISEASE MARKET, BY ARTIFICIAL TEARS, 2024-2032 (IN $ MILLION)
FIGURE 17: NORTH AMERICA DRY EYE DISEASE MARKET, BY PUNCTAL PLUGS, 2024-2032 (IN $ MILLION)
FIGURE 18: NORTH AMERICA DRY EYE DISEASE MARKET, BY SECRETAGOGUES, 2024-2032 (IN $ MILLION)
FIGURE 19: NORTH AMERICA DRY EYE DISEASE MARKET, BY OTHER PRODUCTS, 2024-2032 (IN $ MILLION)
FIGURE 20: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DOSAGE, IN 2023
FIGURE 21: NORTH AMERICA DRY EYE DISEASE MARKET, BY EYE DROPS, 2024-2032 (IN $ MILLION)
FIGURE 22: NORTH AMERICA DRY EYE DISEASE MARKET, BY EYE SOLUTIONS, 2024-2032 (IN $ MILLION)
FIGURE 23: NORTH AMERICA DRY EYE DISEASE MARKET, BY OINTMENTS, 2024-2032 (IN $ MILLION)
FIGURE 24: NORTH AMERICA DRY EYE DISEASE MARKET, BY GELS, 2024-2032 (IN $ MILLION)
FIGURE 25: NORTH AMERICA DRY EYE DISEASE MARKET, BY CAPSULES & TABLETS, 2024-2032 (IN $ MILLION)
FIGURE 26: NORTH AMERICA DRY EYE DISEASE MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2023
FIGURE 27: NORTH AMERICA DRY EYE DISEASE MARKET, BY HOSPITAL PHARMACIES, 2024-2032 (IN $ MILLION)
FIGURE 28: NORTH AMERICA DRY EYE DISEASE MARKET, BY INDEPENDENT PHARMACIES AND DRUG STORES, 2024-2032 (IN $ MILLION)
FIGURE 29: NORTH AMERICA DRY EYE DISEASE MARKET, BY ONLINE PHARMACIES/STORES, 2024-2032 (IN $ MILLION)
FIGURE 30: NORTH AMERICA DRY EYE DISEASE MARKET, COUNTRY OUTLOOK, 2023 & 2032 (IN %)
FIGURE 31: UNITED STATES DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)
FIGURE 32: CANADA DRY EYE DISEASE MARKET, 2024-2032 (IN $ MILLION)